Publication:
First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment

Placeholder

Organizational Units

Program

Authors

Authors

Ozaras, Resat
Mete, Bilgul
Ceylan, Bahadir
Ozgunes, Nail
Gunduz, Alper
Karaosmanoglu, Hayat
Cagatay, Atahan
Gokturk, Kadir
Erdem, Levent
Kocak, Funda

Advisor

Language

Publisher

Journal Title

Journal ISSN

Volume Title

Abstract

Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.

Description

Source:

Keywords:

Keywords

Citation

Ozaras R., Mete B., Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., Cagatay A., Gokturk K., Erdem L., Kocak F., et al., -First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment-, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, ss.774-780, 2014

Endorsement

Review

Supplemented By

Referenced By

0

Views

0

Downloads

View PlumX Details


Sustainable Development Goals

Thumbnail Image
Goal